Is PMS a ‘Disease’ or Market Share?

“A woman’s body is the battlefield where she fights for liberation. It is through her body that oppression works, reifying her, sexualizing her, victimizing her, disabling her.”

~Germaine Greer
The Whole Woman, 1999

Holy Hormones Journal:

Well, Holy Hormones Honey! You learn the most interesting things when perusing the business section of online journals. I have highlighted that statements that I think are the most premenstrual-syndrome-pms-3-638compelling in the report below. The less you know about your hormones, mind, mood and behaviors the larger the market share for the pharmaceutical companies who will develop drug therapies – maybe be even a PMS vaccine? – while taking their profits to the bank.

This is the reality of the situation. Welcome to a behind the scenes view of the planned profits to be made off the part of your body you were not educated about. BTW – what part of your body were you educated about – really? How much do you really know?

BTW- I do like the fact that the report mentioned that the ‘disease’ may be due to low level of vitamin and mineral deficiency…. but ‘disease’ – when did PMS turn into a ‘disease’? This is truly medicalization of women’s bodies. So if you want to prevent the disease – check out the EMPowerplus Q96 on my web site. PMS is not a disease – it is a biochemical, hormonal and nutritional deficiency. The only one who should be profiting off your body is you – and that is with good health.

Premenstrual Syndrome Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020

Digital Journal

Albany, NY — (ReleaseWire) — 10/29/2014 — Premenstrual syndrome (PMS) alternatively known as premenstrual tension is a combination of physical, emotional, psychological disturbances among women of child bearing age. Premenstrual syndrome symptom occurs 1-2 weeks before the onset of menstruation and usually disappears once the menstrual bleeding starts. The exact cause of the disease is though not clear yet fluctuations in hormone level are one of the prominent reasons for onset of symptoms.

Browse the full Premenstrual Syndrome Market Report with TOC

Other associated cause of the disease include low level of vitamin and mineral level, high intake of salty food and frequent alcohol & caffeine consumption. Symptoms of the diseases include acne, swollen breasts, troubled sleeping, muscles pain, mood swings and anxiety disorders. A more severe form of PMS known as premenstrual dysphoric disorder, characterized by repeated transitory cyclic disorder along with increased level of anger, anxiety and tension as compared to PMS disease.

Approximately 20-30% of the menstruating women are believed to be affected by premenstrual syndrome of which 3-8% of them have premenstrual dysphoric disorder. Drugs that are usually employed as therapeutics include nonsteroidal anti-inflammatory drugs which control and regulate symptoms such as abdominal cramps, joint pain and headache. Antidepressants such as fluoxetine, paroxetine and sertraline can also be included in the regular therapy but it must be taken before actual symptoms begin. In premenstrual dysphoric disorder, gonadotropin-releasing hormone (GnRH) agonists such as leuprolide or goserelin can also be employed to regulate rapid fluctuations in the hormone levels.

Nutritional therapy such as vitamin B6, vitamin E, calcium and magnesium along with moderate exercise help in increasing success rate of treatment. Calcium carbonate can be recommended as first-line therapy for women with mild-to-moderate PMS whereas, selective serotonin reuptake inhibitors can be considered as first-line therapy for women with severe PMS complications.

Major drivers to the growth of premenstrual syndrome market includes increasing inclination of key players and government interventions towards developing novel therapeutics as a long term cure to this disease. Awareness and growing concern about premenstrual syndrome especially among women from developed economic countries have effectively contributed towards demand for PMS drugs and diagnostic tests. Till date there is no diagnostic device present to confirm PMS or PMDD yet two of the well-validated scales for the recording of premenstrual symptoms include the Calendar of Premenstrual Experiences (COPE) and the Prospective Record of the Severity of Menstruation (PRISM). Growing demand for hormone therapy based treatment across the globe has tremendously contributed towards increase in revenues and upliftment of PMS market.

Geographically, North America and Europe market are major contributors in terms of revenues and research activities. Availability of advanced diagnostic equipments and healthcare facilities has a major contribution towards growth and development of market in past few years. Rest of the World and Asia-Pacific market are among the most lucrative market for existing as well as new players in forthcoming years owing to large women population base and increasing incidences of lifestyle related disorders in past one decade. Government interventions and campaigns with respect to women health and well-being are effectively contributing towards increasing awareness about Premenstrual syndrome and other associated menstrual disorders in developing economic countries. Some of the pipelined drugs in the market include ProgestoMat, Cis-platinum, CDB-2914, PH80-PMD, Dutasteride and others.


Read full article…


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.